Dyne Therapeutics, Inc. (DYN) company profile
Close on Nov 12, 2026Market cap $3.18BP/E –Yield –
About Dyne Therapeutics
Pharmaceutical Preparations, SIC 2834
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company that develops targeted therapeutics for individuals affected by genetically driven neuromuscular disorders. Utilizing its proprietary FORCE platform, the company conjugates transferrin receptor 1-binding antibody fragments with molecular payloads, including oligonucleotides and enzymes, to deliver therapies directly to muscle tissues and the central nervous system. Its primary pipeline candidates include zeleciment rostudirsen, which addresses Duchenne muscular dystrophy amenable to exon 51 skipping, and zeleciment basivarsen, aimed at treating myotonic dystrophy type 1. Dyne also advances programs targeting facioscapulohumeral dystrophy and Pompe disease, serving patient populations living with these severe genetic conditions.
The company conducts global clinical operations, evaluating its lead product candidates in international trials with regulatory activities spanning the United States and foreign regions. Dyne Therapeutics is incorporated in Delaware and maintains its principal executive offices and headquarters in Waltham, Massachusetts.
Summary of the business section of Dyne Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Dyne Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 1560 Trapelo Road 02451
- Phone
- (781) 786-8230
- Website
- dyne-tx.com
- Employees
- 258, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- DYN
- Exchange
- Nasdaq
- IPO date
- Sep 17, 2020
- Shares outstanding
- 187M, Jul 24, 2026
- Public float
- $948.00M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1818794
- CUSIP
- 26818M108
- ISIN
- US26818M1080
- FIGI
- BBG00NSGPJD0
- Share class FIGI
- BBG00NSGPJF8
- EIN
- 36-4883909
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Cox | CEO & President, Director | 429,507 |
| Douglas Kerr | Head of R&D and CMO | 170,564 |
| Johanna Friedl-Naderer | Chief Commercial Officer | 152,897 |
| Erick Lucera | Chief Financial Officer | 119,766 |
| Richard William Scalzo | SVP, Head of Finance & Admin. | 122,330 |
| Oxana Beskrovnaya | Chief Scientific Officer | 195,840 |
| Brian S. Posner | Director | 27,000 |
| Jason P. Rhodes | Director | 428,946 |
| Dirk Kersten | Director | 3,592,184 |
| Barry E. Greene | Director | – |
| David Charles Lubner | Director | 0 |
| Edward Hurwitz | Director | 4,614,943 |
| Catherine Stehman-Breen | Director | 115,713 |
| Carlo Incerti | Director | 0 |
| Vikram Karnani | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Brumm Josh | $0 | $0 | $1.31M | $165 | $121 |
| FY2025 Cox John G | $2.08M | -$1.77M | $1.31M | $165 | $121 |
| FY2025 Other NEOs | $1.31M | $181.00K | $1.31M | $165 | $121 |
| FY2024 Brumm Josh | $14.38M | $9.76M | $5.56M | $198 | $91 |
| FY2024 Cox John G | $20.69M | $17.01M | $5.56M | $198 | $91 |
| FY2024 Other NEOs | $5.56M | $6.02M | $5.56M | $198 | $91 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| John G. Cox President and Chief Executive Officer | $721.00K | – | $937.89K | $410.97K | $7.01K | $2.08M | -90% |
| Erick Lucera Chief Financial Officer | $391.97K | $691.41K | $1.41M | $197.60K | $6.80K | $2.70M | – |
| Johanna Friedl-Naderer Chief Commercial Officer | $610.69K | – | $243.67K | $232.06K | – | $1.09M | -87% |
| Douglas Kerr Chief Medical Officer | $537.00K | – | $309.53K | $204.06K | $7.01K | $1.06M | -86% |
| Richard Scalzo Former Senior Vice President, Head of Finance and Administration | $107.50K | $166.77K | $106.34K | – | $347.03K | $727.64K | -71% |
| Oxana Beskrovnaya Chief Innovation Officer; Former Chief Scientific Officer | $531.50K | – | $252.15K | $201.97K | $7.01K | $992.63K | -74% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 17, 2020
- Offer price
- $19.00
- Securities offered
- 12,251,578
- Gross proceeds
- $232.78M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Mar 16, 2021
“The initial public offering price is $19.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 27, 2026, we had 258 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 17, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 11, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?